James Watters

Biochemistry, Genetics and Molecular Biology · Life Sciences

26h-index2.9kcitations225works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(97), Eosinophilic Disorders and Syndromes(70), PI3K/AKT/mTOR signaling in cancer(58), Lung Cancer Treatments and Mutations(39), Advanced Breast Cancer Therapies(17)

Publications224 total

Supplementary Table S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 Legend from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary References from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Appendix S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S3 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S5 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Video S1 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Supplementary Table S4 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
2025Open Access
Abstract IA008: Leveraging conformational dynamics for improved selectivity
Molecular Cancer Therapeutics·2024
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary References from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Figure S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Appendix S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Video S1 Legend from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Video S1 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Table S2 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
Supplementary Table S4 from RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
2024Open Access
page 1 of 12Next →

Frequent Co-authors

Howard L. McLeod(13), Donald A. Bergstrom(11), Andrey Loboda(7), Hakan Günaydin(7), Tim Demuth(5), Roberto Valverde(5), David E. Shaw(5), Pearl S. Huang(4), Hongyue Dai(4), Dejan Maglic(4), Kamil Bruderek(4), B. Barry Touré(4), Songping Zhao(4), Patrick J. O’Hearn(4), Demetri T. Moustakas(4), Nastaran Gerami-Moayed(4), Alexander M. Taylor(4), Lindsey Foster(4), Pelin Ayaz(4), Dina A. Sharon(4)